Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Telix Pharmaceuticals Limited logo — See it. Treat it.

Telix Pharmaceuticals Limited

See it. Treat it.

Founded 2015 Australia Australia 1164 employees IPO Total: $1.48B Biotechnology, Pharmaceutical

General Information

Company Name Telix Pharmaceuticals Limited
Founded Year 2015
Location Australia Australia +1
Employees 1164
Industries Biotechnology, Pharmaceutical
Funding Stage IPO
Social

Get notified when Telix Pharmaceuticals Limited moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is carving a niche in the biopharmaceutical industry with its sharp focus on radiopharmaceuticals tailored for oncology and rare diseases. Founded in 2015 and headquartered in Australia, Telix aims to address significant unmet medical needs through innovative solutions. The company operates on a global scale, leveraging its expertise to reach diverse markets.

The company's slogan, "See it. Treat it.", underscores its commitment to precision in both diagnosis and treatment. Telix's presence on both the ASX and Nasdaq underlines its robust market positioning and investor confidence.

In recent developments, Telix secured a substantial $600.00M in a Post-IPO Convertible investment as of 01 April 2026. This significant capital infusion is poised to fuel further growth and innovation, positioning Telix as a promising player in the Biotechnology and Pharmaceutical sectors. Investors should keep an eye on Telix's burgeoning potential and strategic expansion within these critical healthcare domains.

Taxonomy: biopharmaceuticals, radiopharmaceuticals, oncology, rare diseases, molecularly-targeted radiation therapy, prostate cancer, renal cancer, glioblastoma, positron emission tomography, nuclear medicine, molecular imaging, cancer imaging, cancer therapy, urology, clinical-stage biotechnology

Services & Products

Development of therapeutic radiopharmaceuticals
Commercialisation of diagnostic radiopharmaceuticals
Research and innovation in cancer treatment
Global supply, manufacturing, and distribution

Target Customers

Healthcare providers Cancer treatment centers Patients with prostate, kidney, brain, and musculoskeletal cancers Oncologists and radiologists

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Convertible •••••• - 01 Apr 2026
Post Ipo Convertible •••••• - 01 Jul 2024
Grant •••••• 1 •••• •••• 01 Apr 2022
Post Ipo Equity •••••• - 01 Jan 2022
Grant •••••• 1 •••• •••• 01 Mar 2020

View All 7 Funding Rounds

Telix Pharmaceuticals Limited Alternatives & Competitors

Telix Pharmaceuticals Limited vs
Lightpoint
Lightpoint United Kingdom

Improving patient outcomes with targeted cancer surgery

Series C
12 employees
Biotechnology, Medical Devices
Compare Telix Pharmaceuticals Limited vs Lightpoint
Telix Pharmaceuticals Limited vs
IsoTherapeutics
IsoTherapeutics

A Telix Group company

17 employees
Biotechnology
Telix Pharmaceuticals Limited vs
Telix Optimal Tracers, LLC
Telix Optimal Tracers, LLC United States

Contract development and manufacturing for the molecular imaging and pharmaceutical industry

4 employees
Biotechnology, Health Care
Also compare with: Telix Pharmaceuticals Limited vs Akumin® Akumin® Telix Pharmaceuticals Limited vs CANCER CENTER ASSOCIATES CANCER CENTER ASSOCIATES

FAQ About Telix Pharmaceuticals Limited

See it. Treat it.
Telix Pharmaceuticals Limited was founded in 2015.
Telix Pharmaceuticals Limited is headquartered in Australia.
Telix Pharmaceuticals Limited operates in the following industries: Biotechnology, Pharmaceutical.
Telix Pharmaceuticals Limited has approximately 1164 employees.
Telix Pharmaceuticals Limited has completed 7 funding rounds, raising a total of $1.48B. The latest funding stage is IPO.
Telix Pharmaceuticals Limited offers: Development of therapeutic radiopharmaceuticals, Commercialisation of diagnostic radiopharmaceuticals, Research and innovation in cancer treatment, Global supply, manufacturing, and distribution.
Top alternatives and competitors to Telix Pharmaceuticals Limited include Lightpoint, IsoTherapeutics, Telix Optimal Tracers, LLC, Akumin®, CANCER CENTER ASSOCIATES. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Telix Pharmaceuticals Limited and Lightpoint are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Telix Pharmaceuticals Limited and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes